+34 93 169 65 51 info@eignapharma.com

PRAC recommends restrictions on use of fluoroquinolone and quinolone antibiotics following a review of disabling and potentially long-lasting side effects. Once the CHMP has adopted the final opinion, the new restrictions will become applicable in all EU Member States. Keep an eye on https://bit.ly/2ysLFTQfor further information. #pharmacovigilance #PRAC #antibiotics